New drug approval success rate in Europe in 2009

Nature Reviews Drug Discovery

Volumn 9, Issue 5, 2010, Pages 355-356

  Eichler, Hans Georg ^a   Aronsson, Bo ^a   Abadie, Eric ^b   Salmonson, Tomas ^c  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b AFSSAPS   (France)

^c MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE GENITAL SYSTEM; ANTIANEMIC AGENT; AZTREONAM; AZTREONAM LYSINE; BAZEDOXIFENE; BESILESOMAB; BRONCHODILATING AGENT; CANAKINUMAB; CATUMAXOMAB; CAYSTON; CERTOLIZUMAB PEGOL; CONBRIZA; CORIFOLLITROPIN ALFA; DENOSUMAB; DRONEDARONE; ELLAONE; ELTROMBOPAG; EPOETIN THETA; EPORATIO; ESLICARBAZEPINE ACETATE; EXALIEF; GEFITINIB; GOLIMUMAB; INDACATEROL MALEATE; LIRAGLUTIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TC 99M; MULTAQ; ONBREZ BREEZHALER; PLERIXAFOR; PNEUMOCOCCUS VACCINE; PREVNAR 13; PROLIA; PRUCALOPRIDE; REMOVAB; RILONACEPT; SAMSCA; SAXAGLIPTIN; SILODOSIN; SIMPONI; SYNFLORIX; TOLVAPTAN; ULIPRISTAL; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROREC; VINFLUNINE;

ANEMIA; ASCITES; CHRONIC OBSTRUCTIVE LUNG DISEASE; CINCA SYNDROME; CONSTIPATION; DECISION MAKING; DIABETES MELLITUS; DRUG APPROVAL; DRUG CONTROL; DRUG EFFICACY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; EPILEPSY; EUROPE; EUROPEAN UNION; HEART ATRIUM FIBRILLATION; HUMAN; HYPONATREMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LUNG CANCER; LUNG INFECTION; OSTEOMYELITIS; OSTEOPOROSIS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PUBLIC HEALTH; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SHORT SURVEY; UROGENITAL TRACT CANCER;

DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; EFFICIENCY, ORGANIZATIONAL; EUROPE; EUROPEAN UNION; GOVERNMENT AGENCIES; HUMANS;

EID: 77951872182     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3169     Document Type: Short Survey

References (9)

1. Czerepak, E. A. & Ryser, S. Drug approvals and failures: implications for alliances. Nature Rev. Drug Discov. 7, 197-198 (2008).
2. European Commission. Notice to Applicants. Volume 2A: procedures for marketing authorisation. Chapter 1: marketing authorisation. November 2005. EC website [online], http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-2/ a/vol2a-chap1-2005-11pdf (2005).
3. European Medicines Agency. Human medicines. EMA website [online], http://www.ema.europa.eu/index/indexh1.htm (2010).
4. Pignatti, F. et al. The review of drug applications submitted to the European Medicines Evaluation Agency: frequently raised objections, and outcome. Eur. J. Clin. Pharmacol. 58, 573-580 (2002).
5. European Medicines Agency. Withdrawal assessment report for vorinostat MSD 100 mg hard capsules. EMA website [online], http://www.ema.europa.eu/ humandocs/PDFs/EPAR/vorinostatMSD/H-947-WAR.pdf (2008).
6. Regnstrom, J. et al. Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency. Eur. J. Clin. Pharmacol. 66, 39-48 (2010).
7. Hughes, B. 2009 FDA drug approvals. Nature Rev. Drug Discov. 9, 89-92 (2010).
8. Eichler, H.-G. et al. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nature Rev. Drug Discov. 7, 818-826 (2008).
9. European Medicines Agency. Reflection paper on benefit-risk assessment methods in the context of the evaluation of marketing authorisation applications of medicinal products for human use. EMA website [online], http://www.ema. europa.eu/pdfs/human/brmethods/1540407enfin.pdf (2008).